These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

77 related items for PubMed ID: 23302237

  • 1. [Optimizing the individual treatment of neovascular age-related macular degeneration].
    Sun XD, Wang FH.
    Zhonghua Yan Ke Za Zhi; 2012 Oct; 48(10):867-9. PubMed ID: 23302237
    [Abstract] [Full Text] [Related]

  • 2. Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment.
    El-Mollayess GM, Noureddine BN, Bashshur ZF.
    Semin Ophthalmol; 2011 May; 26(3):69-76. PubMed ID: 21609219
    [Abstract] [Full Text] [Related]

  • 3. Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration.
    Gupta B, Adewoyin T, Patel SK, Sivaprasad S.
    Br J Ophthalmol; 2011 Mar; 95(3):386-90. PubMed ID: 20693484
    [Abstract] [Full Text] [Related]

  • 4. [The Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists--comments on the current therapy for neovascular AMD].
    Pauleikhoff D, Bornfeld N, Gabel VP, Holz F, Roider H, German Ophthalmological Society, Retinological Society, Professional Association of Ophthalmologists.
    Klin Monbl Augenheilkd; 2005 May; 222(5):381-8. PubMed ID: 15912454
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Ranibizumab treatment for neovascular age-related macular degeneration: from randomized trials to clinical practice.
    Michalova K, Wickremasinghe SS, Tan TH, Chang A, Harper CA, Downie JA, Hunyor AP, Guymer RH.
    Eye (Lond); 2009 Aug; 23(8):1633-40. PubMed ID: 19648888
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ferrara N, Damico L, Shams N, Lowman H, Kim R.
    Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
    [Abstract] [Full Text] [Related]

  • 13. Visual acuity and its decrease in classic neovascular age-related macular degeneration.
    Behrendt C.
    Ophthalmic Epidemiol; 2004 Dec; 11(5):359-67. PubMed ID: 15590583
    [Abstract] [Full Text] [Related]

  • 14. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K, Sonmez PA, Ozkan SS, Atmaca LS.
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [Abstract] [Full Text] [Related]

  • 15. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.
    Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG.
    Ophthalmology; 2009 Sep; 116(9):1731-9. PubMed ID: 19643495
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.
    Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N.
    Ophthalmology; 2006 Apr; 113(4):623.e1. PubMed ID: 16581423
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.